An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies
Latest Information Update: 19 May 2023
At a glance
- Drugs Tenalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rhizen Pharmaceuticals
- 28 Mar 2023 Status changed from recruiting to completed.
- 19 Jan 2022 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.
- 16 Jan 2022 This trial has been discontinued in Poland according to European Clinical Trials Database record.